Samcyprone is under clinical development by Phio Pharmaceuticals and currently in Phase III for Alopecia Areata. According to GlobalData, Phase III drugs for Alopecia Areata have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Samcyprone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Samcyprone overview
Samcyprone (diphenylcyclopropenone) is under development for the treatment of alopecia areata. The drug candidate is administered through topical route in the form of ointment or gel. It is a new chemical entity (NCE).
It was also under development for the treatment of Verruca vulgaris (common warts) and cutaneous metastases of malignant melanoma.
Phio Pharmaceuticals overview
Phio Pharmaceuticals, formerly known as RXi Pharmaceuticals, is a biotechnology company. The company’s pipeline products include PH-762 for the treatment of stages I, II, and IV cutaneous squamous cell carcinoma (c SCC), stage IV melanoma, and stage IV merkel cell carcinoma; PH-894 is for the treatment of stage IV melanoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), human papillomavirus (HPV) related cutaneous squamous cell carcinoma (c SCC). It also provides clinical trial services. The company partners with academia, biotech and large multi-national organizations for the development of new therapeutics. Phio Pharmaceuticals is headquartered in Marlborough, Massachusetts, the US.
For a complete picture of Samcyprone’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
